Kidney Failure, Chronic Clinical Trial
Official title:
Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)
The Investigator hypothesize that a single dose of patiromer will lower serum potassium levels in less than 6hrs. Since a dosage of 30g/day for a period of 4 weeks has been studied in at least two multicenter randomized controlled trials, the Investigator further hypothesize that a single dose of 25.2g of patiromer will be well tolerated in hyperkalemic patients in the Emergency Department setting. The FDA approved dosage of 25.2g is appropriate for this study because the research staff will enroll patients with moderate (K greater than 6 mEq/L) to severe hyperkalemia, and the higher dosage has typically been used in this population for more effective control.
This is an open label pilot study. Thirty patients with ESRD who qualify for emergent
dialysis on the basis of serum potassium greater than 6mEq/L will be randomly assigned, using
a random number generator in blocks of sixes, to standard-of-care (standard care) or
patiromer group. Patients in the patiromer group will be given a single dose of 25.2g of
patiromer in addition to standard-of-care treatment after randomization. Standard-of-care is
defined as intervention or care provided by clinical provider according to individual
practice pattern or hospital protocol. Each group of 15 patients will be observed with
telemetry monitoring for 10 hours or till hemodialysis units become available for treatment
(whichever comes first). Blood draws and electrocardiograms (ECGs) will be performed at
enrollment and at 1, 2, 4, 6, 8 and 10hrs thereafter. Serum will be analyzed for basic
metabolic panel and magnesium. Medications, including potassium lowering agents, administered
during this period will be documented.
1. Informed consent will be obtained. 2. Subject will be randomized. 3. A. Randomized to
Standard of Care (SOC): data will be collected on SOC treatment. 3. B. Randomized to
patiromer group: subjects will receive a single dose of 25.2g of patiromer. SOC data will be
collected. 4. all subjects will have blood drawn and ECGs (1 12 lead ECG and 1 Lead I Rhythm
strip) done at baseline, 1, 2, 4, 6, 8 and 10 hours. Blood will be analyzed for basic
metabolic panel and magnesium. 5. CRF completion-SOC data will be recorded in addition to
current medications. 6. After subjects have received hemodialysis or reach the 10 hour study
period, whichever comes first, the subject will be completed on the study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03246984 -
VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ
|
N/A | |
Completed |
NCT02922361 -
Spending and Outcomes for Complex Medicare Advantage Patients
|
||
Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
Completed |
NCT01922843 -
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
|
Phase 2 | |
Completed |
NCT01930396 -
Use of Tinzaparin for Anticoagulation in Hemodialysis
|
Phase 4 | |
Completed |
NCT01933789 -
Improving Communication About Serious Illness
|
N/A | |
Not yet recruiting |
NCT01674660 -
Factors Associated With Interdialytic Blood Pressure Variability in Maintenance Hemodialysis Patients
|
N/A | |
Completed |
NCT01209403 -
Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients
|
Phase 4 | |
Not yet recruiting |
NCT01157260 -
The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT00753116 -
Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension
|
Phase 1 | |
Recruiting |
NCT00532688 -
N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure
|
Phase 2/Phase 3 | |
Completed |
NCT00528788 -
How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis
|
Phase 4 | |
Completed |
NCT00534144 -
Comparison Between Effects of Two Iron Preparations on Protein in the Urine
|
Phase 1 | |
Completed |
NCT00226902 -
Vascular Reactivity in Kidney Disease Patients
|
N/A | |
Completed |
NCT00382044 -
Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients
|
N/A | |
Recruiting |
NCT00235287 -
Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT00224081 -
DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)
|
Phase 4 | |
Completed |
NCT00071214 -
Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis
|
Phase 3 | |
Completed |
NCT00049907 -
Cardiac and Renal Disease Study (CARDS)
|
N/A | |
Completed |
NCT00006297 -
Risk Factors for CV Disease in a Dialysis Cohort
|
N/A |